

# PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Ezio Ghigo	09/12/2008
Riccarda Granata	09/12/2008
Aart Jan Van Der Lely	11/17/2008
RECEIVING PARTY DATA	
Name:	Alize Pharma SAS
Street Address:	13, chemin de la Chonchance
City:	Ste-Foy-Les-Lyon
State/Country:	FRANCE
Postal Code:	69 110
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12130615
CORRESPONDENCE DATA	
Fax Number:	(212)527-7701
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	212-527-7700
Email:	nedwards@darbylaw.com
Correspondent Name:	Robert C. Sullivan
Address Line 1:	P.O. Box 770 Church Street Station
Address Line 2:	04518/1209730-US1
Address Line 4:	New York, NEW YORK 10008-0770
ATTORNEY DOCKET NUMBER:	04518/1209730-US1
NAME OF SUBMITTER:	Nicole Edwards
<p>Total Attachments: 4</p> <p>source=Assignment#page1.tif</p>	

CH \$40.00 12130615

**500749011**

**PATENT**  
**REEL: 022076 FRAME: 0462**

source=Assignment#page2.tif

source=Assignment#page3.tif

source=Assignment#page4.tif

**PATENT**

**REEL: 022076 FRAME: 0463**

ASSIGNMENT

WHEREAS, we, EZIO GHIGO, citizen of Italy, and RICCARDA GRANATA, citizen of Italy, and AART JAN VAN DER LELY, citizen of The Netherlands whose full post office addresses are D'Azeglio 22, 10125 Torino, Italy; Giolitti 45, 10123 Torino, Italy; and Papavertuin 14; NL-2662 C'W Bergschenhoek, The Netherlands, (hereinafter collectively referred to as the "Inventors"), have made certain inventions and discoveries disclosed in U.S. Patent Application Serial No. 60/941,186, filed on May 31, 2007, PCT/EP2008/056727 filed on May 30, 2008 and U.S. Patent Application Serial No. 12/130,615, filed on May 30, 2008, entitled: UNACYLATED GHRELIN AS THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISORDERS (hereinafter collectively referred to as the "Applications");

AND WHEREAS, the Inventors executed an Assignment of U.S. Patent Application Serial No. 60/941,186, on June 2, 2007;

AND WHEREAS, ALIZÉ PHARMA SAS, whose full post office address is, 13, chemin de la Chonchance, 69 110 Ste-Foy-Les-Lyon, France, (hereinafter referred to as the "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said inventions and discoveries, and in and to the Applications inclusive of any and all priority rights derived therefrom for any and all countries in the world, and in and to any and all Letters Patent issuing in any and all countries in the world, to be granted for said inventions and discoveries based on said Applications or on patent applications filed in any country claiming priority from any one of said Applications;


NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00), and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we the Inventors, do hereby sell, assign, transfer, and set over, and do hereby confirm any previous sale, assignment or transfer, unto the Assignee, its successors and assigns, our entire right, title, and interest in and to the inventions and discoveries disclosed in the Applications, and in and to the Applications and any continuations or divisions thereof and all priority rights derived therefrom, and in and to any and all patent applications and any continuations or divisions thereof filed in any country claiming priority from any one of the Applications, and in and to all Letters Patent which may be granted upon the Applications or upon patent applications filed in any and all countries in the world including the United States of America, claiming priority from any one of the Applications, and in and to any and all reissues, substitutions, or prolongations thereof; the same to be held and enjoyed by the Assignee for its own use and behoof, and for the use and behoof of its successors and assigns, to the full end of

the term or terms for which said Letters Patent, or reissues, substitutions, or prolongations thereof may be granted, as fully and entirely as the same would have been held and enjoyed by us had this assignment and sale not been made;

AND we hereby agree that, upon request, and without further consideration, but at the expense of the Assignee, we will communicate to the Assignee or its representatives or nominees any facts known to us respecting said inventions and discoveries and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful oaths and generally aid the Assignee, its successors, assigns, and nominees to obtain and enforce proper patent protection for said inventions and discoveries in all countries, and we further agree to execute any and all further papers which may be necessary or desirable to vest or perfect the title of the Assignee, its successors and assigns, in and to said inventions and discoveries, and in and to any and all Letters Patent or reissues thereof which may be granted upon applications in any and all countries in the world.

THIS assignment made effective as of May 30, 2008.


EXECUTED this 12 day of September, 2008.

  
WITNESS

  
EZIO CHIGO

EXECUTED this 12 day of September, 2008.

  
WITNESS

  
RICCARDA GRANATA

EXECUTED this            day of           , 2008.

\_\_\_\_\_  
WITNESS

\_\_\_\_\_  
AART JAN VAN DER LELY

ASSIGNMENT

WHEREAS, we, EZIO GHIGO, citizen of Italy, and RICCARDA GRANATA, citizen of Italy, and AART JAN VAN DER LELY, citizen of The Netherlands whose full post office addresses are D'Azeglio 22, 10125 Torino, Italy; Giolitti 45, 10123 Torino, Italy; and Papaveruin 14; NL-2662 CW Bergschenhoek, The Netherlands, (hereinafter collectively referred to as the "Inventors"), have made certain inventions and discoveries disclosed in U.S. Patent Application Serial No. 60/941,186, filed on May 31, 2007, PCT/EP2008/056727 filed on May 30, 2008 and U.S. Patent Application Serial No. 12/130,615, filed on May 30, 2008, entitled: UNACYLATED GHRELIN AS THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISORDERS (hereinafter collectively referred to as the "Applications");

AND WHEREAS, the Inventors executed an Assignment of U.S. Patent Application Serial No. 60/941,186, on June 2, 2007;

AND WHEREAS, ALIZÉ PHARMA SAS, whose full post office address is, 13, chemin de la Chonchance, 69 110 Ste-Foy-Les-Lyon, France, (hereinafter referred to as the "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said inventions and discoveries, and in and to the Applications inclusive of any and all priority rights derived therefrom for any and all countries in the world, and in and to any and all Letters Patent issuing in any and all countries in the world, to be granted for said inventions and discoveries based on said Applications or on patent applications filed in any country claiming priority from any one of said Applications;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00), and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we the Inventors, do hereby sell, assign, transfer, and set over, and do hereby confirm any previous sale, assignment or transfer, unto the Assignee, its successors and assigns, our entire right, title, and interest in and to the inventions and discoveries disclosed in the Applications, and in and to the Applications and any continuations or divisions thereof and all priority rights derived therefrom, and in and to any and all patent applications and any continuations or divisions thereof filed in any country claiming priority from any one of the Applications, and in and to all Letters Patent which may be granted upon the Applications or upon patent applications filed in any and all countries in the world including the United States of America, claiming priority from any one of the Applications, and in and to any and all reissues, substitutions, or prolongations thereof; the same to be held and enjoyed by the Assignee for its own use and behoof, and for the use and behoof of its successors and assigns, to the full end of

the term or terms for which said Letters Patent, or reissues, substitutions, or prolongations thereof may be granted, as fully and entirely as the same would have been held and enjoyed by us had this assignment and sale not been made;

AND we hereby agree that, upon request, and without further consideration, but at the expense of the Assignee, we will communicate to the Assignee or its representatives or nominees any facts known to us respecting said inventions and discoveries and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful oaths and generally aid the Assignee, its successors, assigns, and nominees to obtain and enforce proper patent protection for said inventions and discoveries in all countries, and we further agree to execute any and all further papers which may be necessary or desirable to vest or perfect the title of the Assignee, its successors and assigns, in and to said inventions and discoveries, and in and to any and all Letters Patent or reissues thereof which may be granted upon applications in any and all countries in the world.

THIS assignment made effective as of May 30, 2008.

EXECUTED this                      day of                      , 2008.

\_\_\_\_\_  
WITNESS


\_\_\_\_\_  
EZIO GHIGO

EXECUTED this                      day of                      , 2008.

\_\_\_\_\_  
WITNESS


\_\_\_\_\_  
RICCARDA GRANATA

EXECUTED this Monday of 17 Nov , 2008.



WITNESS

Karin van der Zwaan

  
AART JAN VAN DER LELY